{"id":"https://openalex.org/W7223117693","doi":"https://doi.org/10.21037/tbcr-2026-0056","title":"Sacituzumab govitecan plus toripalimab compared with toripalimab plus nab-paclitaxel for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer: protocol of a multicenter, open-label, randomized phase II trial","display_name":"Sacituzumab govitecan plus toripalimab compared with toripalimab plus nab-paclitaxel for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer: protocol of a multicenter, open-label, randomized phase II trial","publication_year":2026,"publication_date":"2026-10-01","ids":{"openalex":"https://openalex.org/W7223117693","doi":"https://doi.org/10.21037/tbcr-2026-0056","pmid":"https://pubmed.ncbi.nlm.nih.gov/42991455","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13736023"},"language":"en","primary_location":{"id":"doi:10.21037/tbcr-2026-0056","doi":"https://doi.org/10.21037/tbcr-2026-0056","is_oa":true,"landing_page_url":"https://doi.org/10.21037/tbcr-2026-0056","pdf_url":null,"source":{"id":"https://openalex.org/S4210224147","display_name":"Translational Breast Cancer Research","issn_l":"2218-6778","issn":["2218-6778"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310321814","host_organization_name":"AME Publishing Company","host_organization_lineage":["https://openalex.org/P4310321814"],"host_organization_lineage_names":["AME Publishing Company"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Translational Breast Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.21037/tbcr-2026-0056","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101968817","display_name":"Shaohua Zhang","orcid":"https://orcid.org/0000-0002-2396-6129","observed_orcids":["https://orcid.org/0000-0002-2396-6129"]},"institutions":[{"id":"https://openalex.org/I2802939634","display_name":"Chinese PLA General Hospital","ror":"https://ror.org/04gw3ra78","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2802939634"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Shaohua Zhang","raw_affiliation_strings":["Senior Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Senior Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China","institution_ids":["https://openalex.org/I2802939634"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159171966","display_name":"Jianli Zhao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I157773358","display_name":"Sun Yat-sen University","ror":"https://ror.org/0064kty71","country_code":"CN","type":"education","lineage":["https://openalex.org/I157773358"]},{"id":"https://openalex.org/I4210097354","display_name":"Sun Yat-sen Memorial Hospital","ror":"https://ror.org/01px77p81","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210097354"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jianli Zhao","raw_affiliation_strings":["Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China","institution_ids":["https://openalex.org/I157773358","https://openalex.org/I4210097354"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007088884","display_name":"Xiaoling Ling","orcid":"https://orcid.org/0000-0002-8953-5997","observed_orcids":["https://orcid.org/0000-0002-8953-5997"]},"institutions":[{"id":"https://openalex.org/I4210163492","display_name":"First Hospital of Lanzhou University","ror":"https://ror.org/05d2xpa49","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210163492"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xiaoling Ling","raw_affiliation_strings":["Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China","institution_ids":["https://openalex.org/I4210163492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090541397","display_name":"Xueli Mo","orcid":"https://orcid.org/0009-0007-5343-0302","observed_orcids":["https://orcid.org/0009-0007-5343-0302"]},"institutions":[{"id":"https://openalex.org/I4210139292","display_name":"Peking University Shougang Hospital","ror":"https://ror.org/040rwep31","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210139292"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xueli Mo","raw_affiliation_strings":["Breast Disease Department, Peking University Shougang Hospital, Beijing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Disease Department, Peking University Shougang Hospital, Beijing, China","institution_ids":["https://openalex.org/I4210139292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107229247","display_name":"Man Li","orcid":"https://orcid.org/0000-0003-1672-2190","observed_orcids":["https://orcid.org/0000-0003-1672-2190","https://orcid.org/0000-0002-7660-5896"]},"institutions":[{"id":"https://openalex.org/I191996457","display_name":"Dalian Medical University","ror":"https://ror.org/04c8eg608","country_code":"CN","type":"education","lineage":["https://openalex.org/I191996457"]},{"id":"https://openalex.org/I4210100868","display_name":"Second Affiliated Hospital of Dalian Medical University","ror":"https://ror.org/012f2cn18","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210100868"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Man Li","raw_affiliation_strings":["Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China","institution_ids":["https://openalex.org/I191996457","https://openalex.org/I4210100868"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159162630","display_name":"Herui Yao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I157773358","display_name":"Sun Yat-sen University","ror":"https://ror.org/0064kty71","country_code":"CN","type":"education","lineage":["https://openalex.org/I157773358"]},{"id":"https://openalex.org/I4210097354","display_name":"Sun Yat-sen Memorial Hospital","ror":"https://ror.org/01px77p81","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210097354"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Herui Yao","raw_affiliation_strings":["Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China","institution_ids":["https://openalex.org/I157773358","https://openalex.org/I4210097354"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5159217543","display_name":"Zefei Jiang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802939634","display_name":"Chinese PLA General Hospital","ror":"https://ror.org/04gw3ra78","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2802939634"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Zefei Jiang","raw_affiliation_strings":["Senior Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Senior Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China","institution_ids":["https://openalex.org/I2802939634"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5159162630","https://openalex.org/A5159217543"],"corresponding_institution_ids":["https://openalex.org/I157773358","https://openalex.org/I2802939634","https://openalex.org/I4210097354"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.77645885,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"7","issue":null,"first_page":"51","last_page":"51"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5454000234603882,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5454000234603882,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.41260001063346863,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.017000000923871994,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sacituzumab-govitecan","display_name":"sacituzumab govitecan","score":0.9490000009536743},{"id":"https://openalex.org/keywords/toripalimab","display_name":"toripalimab","score":1.0},{"id":"https://openalex.org/keywords/nab-paclitaxel","display_name":"nab-paclitaxel","score":0.9670000076293945},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.9900000095367432},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8579999804496765},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.6359999775886536},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.734000027179718},{"id":"https://openalex.org/keywords/pd-1-pd-l1-blockade","display_name":"PD-1/PD-L1 blockade","score":0.703000009059906},{"id":"https://openalex.org/keywords/visceral-metastasis","display_name":"visceral metastases","score":0.5770000219345093},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.4740000069141388},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.6520000100135803}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8914999961853027},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.765500009059906},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6466000080108643},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6466000080108643},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5954999923706055},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5527999997138977},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.5311999917030334},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5299999713897705},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4778999984264374},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.447299987077713},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.37940001487731934},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3716999888420105},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3555999994277954},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.34769999980926514},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.34299999475479126},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.3301999866962433},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.32589998841285706},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.3190000057220459},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.3018999993801117},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.3005000054836273},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.2944999933242798},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2913999855518341},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.2847000062465668},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2759000062942505},{"id":"https://openalex.org/C3018260909","wikidata":"https://www.wikidata.org/wiki/Q1322871","display_name":"Exploratory analysis","level":2,"score":0.2667999863624573},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.2644999921321869},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.257999986410141},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.257099986076355},{"id":"https://openalex.org/C187960798","wikidata":"https://www.wikidata.org/wiki/Q7631152","display_name":"Subgroup analysis","level":3,"score":0.251800000667572}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.21037/tbcr-2026-0056","doi":"https://doi.org/10.21037/tbcr-2026-0056","is_oa":true,"landing_page_url":"https://doi.org/10.21037/tbcr-2026-0056","pdf_url":null,"source":{"id":"https://openalex.org/S4210224147","display_name":"Translational Breast Cancer Research","issn_l":"2218-6778","issn":["2218-6778"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310321814","host_organization_name":"AME Publishing Company","host_organization_lineage":["https://openalex.org/P4310321814"],"host_organization_lineage_names":["AME Publishing Company"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Translational Breast Cancer Research","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13736023","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13736023/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13736023/pdf/tbcr-7-51.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Transl Breast Cancer Res","raw_type":"Text"},{"id":"pmid:42991455","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42991455","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.21037/tbcr-2026-0056","doi":"https://doi.org/10.21037/tbcr-2026-0056","is_oa":true,"landing_page_url":"https://doi.org/10.21037/tbcr-2026-0056","pdf_url":null,"source":{"id":"https://openalex.org/S4210224147","display_name":"Translational Breast Cancer Research","issn_l":"2218-6778","issn":["2218-6778"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310321814","host_organization_name":"AME Publishing Company","host_organization_lineage":["https://openalex.org/P4310321814"],"host_organization_lineage_names":["AME Publishing Company"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Translational Breast Cancer Research","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Study Protocol","id":"https://openalex.org/study-designs/study-protocol"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320319721","display_name":"Shanghai Junshi Biosciences","ror":"https://ror.org/0057zjh84"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7223117693.pdf","grobid_xml":"https://content.openalex.org/works/W7223117693.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7116877277","https://openalex.org/W4415507659","https://openalex.org/W7125394157","https://openalex.org/W4416391875","https://openalex.org/W4229445839","https://openalex.org/W4390670334","https://openalex.org/W7161706384","https://openalex.org/W4207017338","https://openalex.org/W4379662255","https://openalex.org/W7162674751"],"abstract_inverted_index":{"Background:":[0],"First-line":[1],"therapeutic":[2],"landscape":[3],"for":[4,60,81,99,303],"advanced":[5,55,131,327],"triple-negative":[6],"breast":[7],"cancer":[8],"(TNBC)":[9],"has":[10],"evolved":[11],"significantly":[12],"following":[13],"recent":[14],"phase":[15,119,251],"III":[16],"studies.":[17],"In":[18,41],"the":[19,74,258,288,310,317],"TORCHLIGHT":[20],"trial,":[21],"toripalimab":[22,103,158,166,264,266,286,323],"plus":[23,84,89,102,157,173,263,267,322],"nab-paclitaxel":[24,33,174,268],"improved":[25],"progression-free":[26],"survival":[27,224],"(PFS)":[28],"versus":[29],"placebo":[30],"combined":[31],"with":[32,54,93,127],"in":[34,73,91,106,140,184,199,269,282,309,324,329],"programmed":[35],"death":[36,63,80],"ligand":[37],"1":[38,65,154,181],"(PD-L1)-positive":[39],"disease.":[40],"ASCENT-03,":[42],"sacituzumab":[43,82,100,146,261,320],"govitecan":[44,83,101,147,262,321],"monotherapy":[45],"demonstrated":[46],"longer":[47],"PFS":[48,191],"than":[49],"chemotherapy":[50,88],"among":[51,247],"untreated":[52],"patients":[53,92,126],"TNBC":[56,328],"who":[57],"were":[58],"ineligible":[59],"anti-programmed":[61],"cell":[62],"protein":[64],"(PD-1)/PD-L1":[66],"treatment.":[67],"ASCENT-04/KEYNOTE-D19":[68],"reported":[69],"a":[70,107,185,270,297],"significant":[71],"reduction":[72],"risk":[75],"of":[76,216,260,285,296,319],"disease":[77,238],"progression":[78],"or":[79,132,165],"pembrolizumab":[85,90],"compared":[86],"to":[87,143,220,256,274],"PD-L1-positive":[94,109,134,299,326],"tumor.":[95],"However,":[96],"prospective":[97],"evidence":[98],"is":[104,190,254],"lacking":[105],"China-relevant":[108],"population.":[110],"Methods:":[111],"This":[112,250,313],"multicenter,":[113],"open-label,":[114],"randomized,":[115],"exploratory":[116,208],"superiority,":[117],"parallel-group":[118],"II":[120,252],"trial":[121,253,314],"(NCT07040644;":[122],"protocol":[123],"CO-US-979-7331)":[124],"enrolls":[125],"treatment-na\u00efve":[128],"unresectable":[129],"locally":[130,289],"metastatic":[133],"TNBC.":[135],"Patients":[136],"are":[137],"randomly":[138],"assigned":[139],"equal":[141],"proportions":[142],"receive":[144],"either":[145],"at":[148,159,167,175],"10":[149],"mg/kg":[150],"intravenously":[151],"(IV;":[152],"days":[153],"and":[155,182,207,227,243,301],"8)":[156,183],"240":[160,168],"mg":[161,169],"IV":[162,170,179],"(day":[163,171,180],"1)":[164,172],"125":[176],"mg/m":[177],"2":[178],"3-week":[186],"cycle.":[187],"Primary":[188],"endpoint":[189],"assessed":[192],"by":[193],"investigators":[194],"per":[195],"Response":[196],"Evaluation":[197],"Criteria":[198],"Solid":[200],"Tumors":[201],"(RECIST)":[202],"version":[203],"1.1.":[204],"Key":[205],"secondary":[206],"endpoints":[209],"encompass":[210],"objective":[211],"response":[212,217,221],"rate":[213],"(ORR),":[214],"duration":[215],"(DoR),":[218],"time":[219],"(TTR),":[222],"overall":[223],"(OS),":[225],"safety,":[226],"subgroup":[228],"analyses,":[229],"including":[230],"visceral":[231],"metastasis":[232],"status,":[233,239],"prior":[234,244,304],"curative-setting":[235],"anti-PD-(L)1":[236],"exposure,":[237],"disease-free":[240],"interval":[241],"(DFI),":[242],"taxane":[245],"therapy,":[246],"others.":[248],"Discussion:":[249],"designed":[255],"evaluate":[257],"superiority":[259],"over":[265],"treatment":[271],"setting":[272],"relevant":[273],"Chinese":[275],"practice.":[276],"Notable":[277],"design":[278],"features":[279],"include":[280],"enrollment":[281],"China,":[283],"use":[284],"as":[287],"approved":[290],"immune":[291,305],"checkpoint":[292,306],"inhibitor":[293,307],"partner,":[294],"inclusion":[295],"broader":[298],"population,":[300],"allowance":[302],"exposure":[308],"curative":[311],"setting.":[312],"may":[315],"clarify":[316],"role":[318],"first-line":[325],"China.":[330],"Trial":[331],"Registration:":[332],"ClinicalTrials.gov,":[333],"NCT07040644;":[334],"URL:":[335],"https://clinicaltrials.gov/study/NCT07040644":[336]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-10-22T00:00:00"}